Evergreen Nephrology, a provider of tech-enabled value-based kidney care services in the U.S., raised $130 million in equity funding.
Rubicon Founders and Oak HC/FT co-led the investment round with the participation of K2 HealthVentures.
With fresh funds, further expanded its value-based care services in more states across in U.S. Presently, it is operating across 24 states with a network of over 900 providers, it delivers personalized, value-based care designed to empower patients and improve outcomes.
“This investment enables us to broaden access to care programs that improve patient outcomes while driving down healthcare costs,” said John Donlan, CEO of Evergreen Nephrology. “We are dedicated to creating lasting, positive change for patients and families affected by chronic kidney disease.”
According to data provided by Evergreen Nephrology, over 37 million Americans are currently living with chronic kidney disease, with Medicare spending on the treatment of chronic kidney disease exceeding $95 billion annually.
Evergreen Nephrology takes a collaborative approach to kidney care by partnering closely with nephrologists to enhance patient outcomes. The company offers nephrologists wraparound support through analytical insight and tools, and a dedicated care team for their patients consisting of nurse care managers, care coordinators, social workers, dietitians, and pharmacists. This interdisciplinary model ensures that patients receive holistic and personalized care while enabling nephrologists to focus on their clinical expertise and leadership in managing kidney disease.
“The healthcare system has long overlooked the critical need to empower nephrologists in the delivery of advanced kidney care management,” said Matt Kim, Partner at Rubicon and Co-Founder of Evergreen Nephrology.
“By equipping nephrologists with the tools, resources, and support they need, Evergreen is bridging a crucial gap in healthcare and enabling a more effective, collaborative approach to managing kidney disease,” added Matt Kim.